Outcomes4Me Showcases Mika Clinical Evidence and Collaboration at German Cancer Congress

According to a recent LinkedIn post from Outcomes4Me Inc, the company’s Outcomes4Me/Mika team engaged with stakeholders across the oncology ecosystem at the German Cancer Congress. The post highlights the presentation of OnkoDigiTrial II study results by Franziska Springer, which are described as demonstrating the effectiveness of the Mika app.

The post also notes discussions with representatives from patient advocacy organization yeswecan!cer, focused on patient-centric collaboration in oncology. For investors, this suggests ongoing efforts by Outcomes4Me to validate its digital therapeutic offering through clinical evidence and to deepen ties with patient-focused partners, potentially supporting future adoption and reimbursement prospects in European oncology markets.